Preview

Regulatory Research and Medicine Evaluation

Advanced search

Peculiarities of the Regulatory Status of Radiopharmaceuticals Manufactured in Medical Organisations

https://doi.org/10.30895/1991-2919-2022-12-4-389-394

Abstract

Radiopharmaceuticals, the medicinal products containing radioactive isotopes, hold a special place among the other medicines. The aim of the study was to analyse regulatory peculiarities of the production and subsequent life cycle of radiopharmaceuticals, associated with the unique physicochemical properties, production process, distribution, and clinical use. The article reviews regulatory decisions adopted in Russia and a number of other countries that, in certain circumstances, allow medical organisations not licensed as manufacturers to compound radiopharmaceuticals for in-house use without marketing authorisation. Unstable isotopes in radiopharmaceuticals reduce the risk of microbial contamination, so the quality control requirements may be relaxed. The described regulatory framework, which came into effect 12 years ago, provided an opportunity for a many-fold increase in the number of radiopharmaceuticals for radionuclide diagnosis and treatment of severe socially significant diseases. In recent years, a number of countries have adopted regulations making it possible to  supply the  radiopharmaceuticals manufactured by medical organisations outside the usual marketing authorisation track to other medical organisations. If adopted in Russia, a similar regulation will further expand the access to effective methods of diagnosis and treatment for patients.

About the Authors

S. V. Shatik
A.M. Granov Russian Research Centre for Radiology and Surgical Technologies
Russian Federation

Sergey V. Shatik, Cand. Sci. (Biol.)

197758, St. Petersburg, Pesochny, Leningradskaya St., 70



D. N. Maystrenko
A.M. Granov Russian Research Centre for Radiology and Surgical Technologies
Russian Federation

Dmitry N. Maystrenko, Dr. Sci. (Med.)

197758, St. Petersburg, Pesochny, Leningradskaya St., 70



A. A. Stanzhevskiy
A.M. Granov Russian Research Centre for Radiology and Surgical Technologies
Russian Federation

Andrey A. Stanzhevskiy, Dr. Sci. (Med.)

197758, St. Petersburg, Pesochny, Leningradskaya St., 70



References

1. Trends in radiation sterilization of health care products. Vienna: International Atomic Energy Agency; 2008.

2. Чудаков ВМ, Жуйков БЛ, Ермолаев СВ, Коханюк ВМ, Мостова МИ, Зайцев ВВ и др. Исследование характеристик генератора 82 Rb для позитронно-эмиссионной томографии. Радиохимия. 2014;56(5):455–61. https://doi.org/10.1134/S1066362214050142

3. Chudakov VM, Zhuikov BL, Ermolaev SV, Kokhanyuk VM, Mostova MI, Zaitsev VV, et al. Characterization of a 82 Rb generator for positron emission tomography. Radiochemistry. 2014;56(5):535–43 https://doi.org/10.1134/S1066362214050142

4. Pijarowska-Kruszyna J, Garnuszek P, Decristoforo C, Mikołajczak R. Radiopharmaceutical precursors for theranostics. In: Eppard E, ed. Theranostics: an old concept in new clothing. IntechOpen; 2021. P. 3–22.


Supplementary files

Review

For citations:


Shatik S.V., Maystrenko D.N., Stanzhevskiy A.A. Peculiarities of the Regulatory Status of Radiopharmaceuticals Manufactured in Medical Organisations. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2022;12(4):389-394. (In Russ.) https://doi.org/10.30895/1991-2919-2022-12-4-389-394

Views: 504


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 3034-3062 (Print)
ISSN 3034-3453 (Online)